No Data
No Data
No Data
No Data
No Data
Kiniksa Pharmaceuticals Faces Capital Raising Hurdles Amid Stricter UK Shareholder Voting Laws
TipRanksApr 27 14:00
Analyst Estimates: Here's What Brokers Think Of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) After Its First-Quarter Report
Yahoo FinanceApr 26 18:37
Kiniksa Pharmaceuticals Is Maintained at Outperform by Evercore ISI Group
Kiniksa Pharmaceuticals Is Maintained at Outperform by Evercore ISI Group
Dow JonesApr 25 01:50
Evercore ISI Group: Maintaining the Kiniksa Pharmaceuticals (KNSA.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $25.00 to $30.00.
Evercore ISI Group: Maintaining the Kiniksa Pharmaceuticals (KNSA.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $25.00 to $30.00.
Zhitong FinanceApr 25 01:40
Evercore ISI Group Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $30
Evercore ISI Group analyst Liisa Bayko maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Outperform and raises the price target from $25 to $30.
BenzingaApr 25 01:39
Kiniksa Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/24/2024 63.49% Evercore ISI Group $25 → $30 Maintains Outperform 01/02/2024 36.24% Wedbush $23 → $25 Ma
BenzingaApr 25 01:38
No Data
No Data